Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
58 active Medicare policies list M32.9, and 16 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
16 policies from 4 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M32.9 |
|---|---|---|
| ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) | Oct 26, 2023 | Covered |
| Bortezomib Products | Feb 2, 2024 | Covered |
| Extracorporeal Immunoadsorption (Prosorba Column) | Jun 5, 2023 | Covered |
| Extracorporeal Photochemotherapy (Photopheresis) | Mar 29, 2023 | Covered |
| Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications | Aug 31, 2023 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) |
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Sep 18, 2017
JM · Effective Sep 18, 2017
J15 · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J6 · Effective Nov 1, 2022
JK · Effective Nov 1, 2022
J6 · Effective Nov 1, 2022
JK · Effective Nov 1, 2022
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
JL · Effective Oct 1, 2025
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Mar 5, 2026
J5 · Effective Jul 1, 2026
J6 · Effective Jul 1, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2025
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2025
J6 · Effective Apr 1, 2026
J9 · Effective Oct 1, 2024
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Apr 16, 2026
J9 · Effective Oct 1, 2023
| Feb 20, 2024 |
| Covered |
| Optic Nerve and Retinal Imaging Methods | May 17, 2023 | Covered |
|---|
| Polymerase Chain Reaction Testing: Selected Indications | Feb 9, 2024 | Covered |
|---|
| Policy | Effective | Status of M32.9 |
|---|---|---|
| Fundus Photography | Apr 15, 2026 | Covered |
| Gamma Glutamyl Transferase Testing | Jul 1, 2026 | Covered |
| Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid Tumors | Jul 1, 2026 | Covered |
| Therapeutic Apheresis | Apr 15, 2026 | Covered |
| Therapeutic use of Stem Cells, Blood and Bone Marrow Products | Oct 1, 2026 | Not covered |
| Policy | Effective | Status of M32.9 |
|---|---|---|
| Benlysta (Belimumab) | Dec 1, 2025 | Covered |
| Saphnelo (Anifrolumab-Fnia) | Jul 1, 2026 | Covered |
| Policy | Effective | Status of M32.9 |
|---|---|---|
| Pulmonary Function Testing | Not recorded | Covered |